The Japanese Ministry of Health approves the drug "paricetinib" to treat Corona
The Japanese Ministry of Health announced that it has approved the use of baricetinib, a treatment for rheumatoid arthritis by Eli Lilly and Insight, in the treatment of Covid-19 patients.
The ministry approved the use of the drug with remdesivir for pneumonia patients who need oxygen for treatment, according to Bloomberg News.
It is noteworthy that it is the third drug approved for treating Covid-19 patients in Japan, along with remdesivir and dexamethasone.
On Friday, Japan intends to declare a state of emergency again in Tokyo and three other prefectures, as regions face another wave of Covid-19 infections.
In mid-February, Japan began a campaign of vaccinations against the Corona virus, but at a very slow pace.
Only 0.7 percent of the population has been fully vaccinated so far, according to the Prime Minister's Office.
Japan imposed a nationwide state of emergency for a month in April, although the measure was already in effect in some provinces for a month and a half.
It declared a state of emergency again in 11 prefectures, including Tokyo and Osaka, in January.
It was raised in Tochigi in February and in other provinces in March.
Follow our latest local and sports news, and the latest political and economic developments via Google news